Dr. Mike McCullar, CEO of RegCell, is developing a novel cell therapy to treat autoimmune diseases that specifically addresses the loss of tolerance, in which the immune system mistakenly attacks the body's own tissues. This approach contrasts with current treatments, which broadly suppress the immune system and may cause side effects. The key goals of the therapy are to achieve long-term disease control and restore the immune system's natural balance. The company's manufacturing process is designed to simplify cell therapies, making them more affordable and accessible to a broader population of autoimmune patients.

Mike explains, "The real driver of immunity, we believe, is what's called loss of tolerance, which is a system in our bodies that protects us from bad immune cells that attack our tissues. So that's a fundamental limitation in biology, and there really is not a curated treatment at this point. So our view has really been to try to restore the natural balance of our immune system by regulatory T cells, which are an indispensable non-redundant cell type to maintain tolerance against our autoimmune disorders. So we think the current treatments really don't address these challenges. They are broadly suppressing the immune system, and they don't offer curative potential."

"We've been using the same kinds of drugs for the immune disease for about three to five years, and they will broadly suppress the immune system. They are really unable to distinguish between a good immune cell and a bad immune cell. And I think that's the fundamental limitation of how these drugs work. They could be very affected, but they do really broadly suppress the immune system in an indiscriminate way."

#RegCell #AutoimmuneHepatitis #Biotechnology #MedicalResearch#AutoimmuneDiseases #CellTherapy #PrecisionMedicine #Immunology #Biotech #RegulatoryTCells #Innovation #HealthcareTechnology #ClinicalTrials

regcellbio.com

Download the transcript here

Amy Mendoza, Chief Marketing Officer at Alphaeon Patient Financing, highlights the advantages of working with a finance company that provides options for treatments in cosmetic, dental, vision, audiology, and veterinary care. This is an approach for patients who might delay or forgo treatment and preventive care due to cost, including those with average credit or who need subprime options. Working with providers, Alphaeon helps grow their practices and improve patient experience and outcomes.

Amy explains, "I think the most charming and attractive part of Altheon in healthcare is that it is opening access and providing solutions for patient financing. This includes access to treatments that providers can offer in healthcare markets, including cosmetic, dental, vision, audiology, and now veterinary care."

"Financing is access. And so it's not that patients lack a desire for care, they're lacking affordable pathways. And so, being able to deliver and present the right financing solutions opened the door to preventive care before something becomes urgent and to completing full treatment plans instead of piecemeal care. And then maybe more especially impactful for middle-income patients and families and patients without robust insurance benefits. So when patients can say yes to care earlier, outcomes improve, and that's clinically and financially."

"The setup is pretty straightforward, and the reality is the fees and terms are much more friendly, giving them the opportunity to open up a revolving access or line of credit that they can apply to taking care of their pet within the family, or maybe dental or vision, and support a handful of members within the immediate family."

#Alphaeon #PatientFinancing #HealthcareFinancing #PatientAccess #HealthTech #MedicalFinancing #HealthcareInnovation #PatientCare #HealthcareLeadership #DigitalHealth #FinTech #Healthcare

goalphaeon.com

Download the transcript here

Dane Stevens, Founder, is CEO and Director at Optimi Health, a Canadian company that manufactures MDMA and naturally derived psilocybin from mushrooms for use in therapy for PTSD and treatment-resistant depression. These psychedelic-based mental health treatments are being used in the regulated market in Australia and in Special Access programs in Canada, and showing real-world evidence of a positive impact. Dane emphasizes the importance of a clinical setting for the administration of psychedelic medicines and integration with traditional therapy.

Dane explains, "We exist to support the responsible use of psychedelic medicines within regulated healthcare systems. We are a manufacturer of both MDMA and psilocybin, and our company exports those products to the only truly regulated market in the world right now, which is Australia. There, our MDMA is being prescribed for PTSD, and our psilocybin, naturally derived psilocybin extract, is being prescribed for treatment-resistant depression. And so we're not your classic drug developer. We're on a mission to be in the clinic and inpatient today, and that's where we are."

"Right now, they're still scheduled substances, but in Canada specifically, you have what's called the Special Access Program, where if you're suffering from end-of-life distress or PTSD in a very serious way or treatment-resistant depression, you can apply directly to the health minister for an exemption to access psychedelics. But they are still scheduled and restricted."

"If you're looking at just the Australian model in Australia, they rescheduled specifically MDMA for the use in PTSD treatment. Specifically, around psilocybin, it's only to be used for treatment-resistant depression. And so, when we, as a company, actually export directly from Canada to Australia, the permits say it's only to be used within that framework. So it's not a take-home medicine, it's all done within the guidance of your healthcare professional at the clinic."

#OptimiHealth #PsychedelicMedicine #MentalHealth #PTSD #Depression #Innovation #Healthcare #Australia #TreatmentResistantDepression #Psilocybin #MDMA #PsilocybinTherapy #MDMATherapy #MentalHealthInnovation #FDAApproval #HealthPolicy #CanadaHealth #ClinicalResearch #RealWorldEvidence

optimihealth.ca

Download the transcript here

Renzo Luzzatti, Founder and CEO of US-Rx Care, discusses the role and practice of the Pharmacy Benefits Managers and the advantages of working with a company that uses a fiduciary model. Inherent conflicts of interest in the traditional PBM model, such as manufacturer rebates and requirements to use PBM-owned pharmacies, drive up prescription drug costs. US-Rx Care eliminates these conflicts by charging a flat administrative fee with its sole incentive to lower drug costs for the plan and its members.

Renxo explains, "We've been around since 2007. We do have about 5 million lives under management, both self-funded employers, which is the bulk of our business. Then we also tap into Medicare health plans and have some programs and offerings that we assist there to lower costs and improve the quality of care. Our approach is unique in that we've taken a fiduciary stance from day one. We can talk about that in a little bit. It is a legal term. It's defined under ERISA, which governs health plans. They have a fiduciary duty to the plan, the members, and the management of the plan assets. And the industry as a whole has shied away from any fiduciary obligation whatsoever, in part because it's rife with conflicts of interest, and you cannot have conflicts of interest as a fiduciary."

"That is really at the core of all of the issues and complaints that we're hearing about PBMs - they're driving up the cost of prescriptions rather than having the intended effect, which is to reduce the cost of prescriptions. And I would say in the last four or five years, employers have really started to ask the right questions because they're becoming more and more educated."

"For folks like us, we're growing like crazy because the industry finally gets that. The deal that they were getting through their traditional model is not so good. The other thing is when we move to a fiduciary model, savings are typically in the realm of 30% to 50% in the first year, and then we typically see additional savings in year two and three, and then after that, the goal and the intent, which we've been successful at, is to keep costs stable."

#USRxCare #PBM #PharmacyBenefits #EmployeeBenefits #HealthcareCosts #FiduciaryResponsibility #BenefitsConsulting #HealthcareTransparency #CostContainment #SelfFundedEmployers #HealthcareReform

usrxcare.com

Download the transcript here

Kory Daniels, Chief Security and Trust Officer at LevelBlue, discusses the multifaceted cybersecurity challenges in the healthcare industry and the risks posed by legacy systems not designed for secure internet connectivity. Artificial intelligence is being used successfully to defend against cyber attacks, while threat actors are using AI without ethical constraints to launch sophisticated attacks. Managing cybersecurity includes using digital twins to model vulnerabilities and to develop strategies for identity and access management for human and non-human identities, such as robots and AI agents.

Kory explains, "We must recognize that we're not starting from a clean slate - we have a lot of decades-old systems operating both within the physical footprint of the healthcare and hospital facility and in record retention and data management. Many organizations are looking at how to get ahead in identifying what needs to happen to embrace new technology and much of the innovation. At the same time, being conscious and cognizant of opportunities to retrofit, taking what's there already today and making it internet-connected as an example, making it Internet of Things-connected so that devices that weren't purpose-built to communicate to the internet now can communicate to the internet, but it creates some risks and it poses some challenges."

"We highlighted that some of these legacy systems or initial systems that have been in the organization for years, some 10 years or more, were not necessarily purpose-built or designed at the time of manufacturing, nor with the software needed for those tools to operate with current speed, expectations, and requirements. Healthcare entities are engaging both patients and supporting care doctors and patient care professionals in 2026 and beyond."

#LevelBlue #HealthcareCybersecurity #DigitalTransformation #AIinHealthcare #LegacySystems #PatientSafety #CyberThreats #HealthTech #DataSecurity #MedicalDevices #DigitalHealth #HealthcareIT #CyberDefense #HealthcareInnovation #RiskManagement #ComplianceMatters

LevelBlue.com

Download the transcript here

Chase Idleman, Chief Executive Officer of Arlow, is leveraging emerging AgeTech and the longevity economy to develop solutions for an aging population, their families, and caregivers. With a human-centered approach to the entire aging process, Arlow uses AI to create a system for action for adults over 65 and their support networks. The main goal is to make tasks like care coordination, document management, medication adherence, and detecting changes in behavior and physical abilities easier.

Chase explains, "AgeTech is more around the people in the population. So if you look at aging, it is not one point in time, but is truly a continuum and impacts so many people. It's not just the person who's aging, but also the family members and the entire circle of care around them. So, AgeTech is that kind of emerging field, which is how I try to differentiate it. Again, it's not product-centric, but it is really human-centric over a continuum of time."

"What we felt was the biggest opportunity was not only creating a solution for older adults, but creating a solution for the circle of care, the people every single day who are helping those older adults. And in parallel, we really started to lean in on this employer front with the workforce. So in the workforce environment, it's pretty interesting, 25% of FMLA is for caregiving. And right now, there's not a ton of solutions that can support them. So those workers are essentially the circle of care."

#Arlow #AgeTech #AI #Healthcare #Aging #Innovation #DigitalHealth #Longevity #Caregiving #HealthTech #SeniorCare #FamilyCaregivers #CaregiverBurnout #OlderAdults #EmployeeBenefits #EmployeeAssistantPrograms

Arlow.ai

Download the transcript here

Dr. Ivan Horak, Founder and CEO of Tikva Allocell, is focused on next-generation allogeneic cell therapies using modified T-cells from healthy donors to make these therapies more scalable, accessible, and affordable. Using virus-specific T-cells, this approach is showing effectiveness against solid tumors, which are difficult for traditional CAR-T therapies to treat. The primary target is an antigen found particularly in Epstein-Barr virus-associated malignancies and is showing potential for treating autoimmune diseases as well as cancer.

Ivan explains, "Cell therapy has a long history. We started with many scientists, but probably the godfather of the technology, Zelig Eshhar, who's not with us anymore. He passed away last year. The idea behind that was to use patient cells and modify them and use them as a fighter against the cancer. But over time, we realized over the last two decades that it's very useful, very successful in the treatment of hematologic malignancies, but it's very expensive and labor-intensive. The question was how to enhance this technology and bring it to more patients in a friendly and affordable way."

"The second generation are therapies where we are using healthy people's cells, primarily T-cells, but can be NK cells, can be gamma-delta T-cells. And these cells are being modified, and they are infused into a patient. The advantage of this technology is that patients are identified, and the provider can request the cell from different biotechnology companies, which can be available within the next few days, because from one healthy donor, you can make multiple doses for patients."

#TikvaAllocell #CellTherapy #CancerResearch #Immunotherapy #Biotechnology #Biotech #Innovation #ClinicalTrials #AllogeneicTherapy #Allogeneic #SolidTumors #NextGenTherapy #PrecisionMedicine #CellTherapy #CART #Oncology #ImmuneOncology #CellandGeneTherapy

tikvaallocell.com

Download the transcript here

Tyrone Lam, is Chief Business Development Officer at GATC Health, a company that has developed a predictive AI model to derisk and accelerate drug discovery and development. A significant partnership with Lloyd's of London to use this technology to underwrite insurance for clinical trials enables the insurer to base financing decisions on objective reports that predict a drug's safety and efficacy with high accuracy. There is potential for this technology to become a standard for biotech investment, reducing reliance on animal testing and enabling more efficient development of drugs for smaller patient populations.

Tyrone explains, "GATC Health is a technology company that is de-risking and accelerating the drug discovery and drug development process. So at a higher level, our mission is to take as much of the financial and scientific risk out of the drug discovery business as possible, which would enable better, safer, and more available drugs to be available for humans."

"Our overall platform is called Operon that has literally hundreds of AI models built in that basically do three things. One is that we're able to discover and validate in silico the targets in the body associated with a particular disease. And then the second piece of our platform broadly is the ability to generate novel compounds to treat those diseases. And then we created off of Operon an independent validation that would run in silico, like an AI-generated clinical trial to understand how those novel drugs would perform against those targets in human physiology."

"That third part of the platform is where we created a product called Derisq, and that is an independent, objective report that we can run on other people's drugs, biotech pharma's drug candidates, to give them a very rapid indication of how that drug's going to perform in a human clinical trial."

#GATCHealth #DrugDiscovery #AIinHealthcare #PharmaInnovation #ClinicalTrials #HealthTech #MedicalAI #Biotechnology #PrecisionMedicine #HealthcareInnovation #FutureOfMedicine #DrugDevelopment #AIplatform #DueDiligence #DeriskingBiotech #Derisq #CapitalEfficiency #RiskIntelligence #BiotechInvesting

GATCHealth.com

Download the transcript here